XML 82 R65.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Identifiable Intangible Assets and Goodwill - Finite-lived Intangible Assets Percentage of Total Intangibles (Details) | Oct. 01, 2017
--- | ---
Operating Segments [Member] | Developed Technology Rights [Member] | IH [Member] |
Finite-Lived Intangible Assets [Line Items] |
Percentage of total identifiable intangible assets, less accumulated amortization | 68.00%
Operating Segments [Member] | Developed Technology Rights [Member] | EH [Member] |
Finite-Lived Intangible Assets [Line Items] |
Percentage of total identifiable intangible assets, less accumulated amortization | 32.00%
Operating Segments [Member] | Brands [Member] | IH [Member] |
Finite-Lived Intangible Assets [Line Items] |
Percentage of total identifiable intangible assets, less accumulated amortization | 75.00%
Operating Segments [Member] | Brands [Member] | EH [Member] |
Finite-Lived Intangible Assets [Line Items] |
Percentage of total identifiable intangible assets, less accumulated amortization | 25.00%
Pfizer's Worldwide Research and Development [Member] | Segment Reconciling Items [Member] | Developed Technology Rights [Member] |
Finite-Lived Intangible Assets [Line Items] |
Percentage of total identifiable intangible assets, less accumulated amortization | 0.00%
Pfizer's Worldwide Research and Development [Member] | Segment Reconciling Items [Member] | Brands [Member] |
Finite-Lived Intangible Assets [Line Items] |
Percentage of total identifiable intangible assets, less accumulated amortization | 0.00%

X
- Definition Intangible Assets, Net, Percentage of Intangible Assets, Net + References No definition available. + Details
Name: | pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet
Namespace Prefix: | pfe_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=pfe_InnovativeHealthSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=pfe_EssentialHealthSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=pfe_PfizersWorldwideResearchandDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |